

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/23804>

Please be advised that this information was generated on 2017-12-05 and may be subject to change.



Effects on Transmethylation by High-Dose 6-Mercaptopurine and Methotrexate Infusions During Consolidation Treatment of Acute Lymphoblastic Leukemia

Carin W. Keuzenkamp-Jansen,*†‡ Ronney A. De Abreu,*†
Henk J. Blom,* Jos P. M. Bökkerink† and J. M. Frans Trijbels*

*LABORATORY OF PEDIATRICS, AND †CENTER FOR PEDIATRIC ONCOLOGY S.E. NETHERLANDS, UNIVERSITY HOSPITAL ST. RADBOUD, P.O. BOX 9101, 6500 HB NIJMEGEN, THE NETHERLANDS

ABSTRACT. 6-mercaptopurine (6MP) cytotoxicity is caused by thioguanine and methylthioinosine nucleotides. Thiopurine methylation occurs to a large extent *in vivo* and *in vitro*. In this reaction, S-adenosyl-L-methionine (AdoMet), produced from methionine and ATP, is converted into S-adenosyl-L-homocysteine (AdoHcy) which, in turn, is hydrolyzed into homocysteine. Remethylation of homocysteine into methionine is inhibited by methotrexate (MTX). In cultured lymphoblasts, AdoMet:AdoHcy ratio and DNA methylation decrease after incubation with 6MP. The aim of the present study was to investigate the influence of high-dose 6MP on the methylation capacity in children with acute lymphoblastic leukemia.

Five patients received 4 courses with high-dose intravenous MTX ($5 \text{ g} \cdot \text{m}^{-2}$ in 24 hr) immediately followed by high-dose 6MP ($1300 \text{ mg} \cdot \text{m}^{-2}$ in 24 hr). Five control patients received high-dose MTX and oral 6MP ($25 \text{ mg} \cdot \text{m}^{-2}$ daily for 8 weeks). Leucovorin rescue was started at 36 hr in both groups.

In the intravenous 6MP group, 6-methylmercaptopurine, its riboside, and 6-methylmercapto-8-hydroxypurine were detectable in plasma in concentrations of 0.3–2.6 μM (6MP steady state levels: 11.6 μM). In red blood cells, mean methylthioinosine nucleotide levels were one third of those of ATP ($13.1 \text{ nmol}/10^8$). AdoHcy levels ($10 \text{ pmol}/10^8$) remained constant in both groups and AdoMet was not detectable ($<20 \text{ pmol}/10^8$). In both groups, plasma homocysteine increased and methionine decreased following administration of MTX. The delay in the recovery of methionine in the intravenous 6MP group after MTX infusion is probably the result of an increased demand on methyl groups during 6MP infusion. *BIOCHEM PHARMACOL* 51;9:1165–1171, 1996.

KEY WORDS. 6-mercaptopurine; methotrexate; acute lymphoblastic leukemia; methylation

6MP§ is used in the treatment of ALL. It has no intrinsic cytotoxic activity, but is converted into active metabolites intracellularly (Scheme 1). 6MP is first converted with 5-phosphoribosyl-1-pyrophosphate as cosubstrate into tIMP which, itself, can be converted either into tGMP or MetIMP. Both pathways result in cytotoxicity *in vitro*, either by incorporation of thioguanine nucleotides into DNA and RNA [1, 2] or by inhibition of purine *de novo* synthesis by MetIMP [2, 3]. 6MP is methylated into MeMP and 6MP-riboside into MeMPR (Scheme 1). The thiopurine methylation reactions are catalyzed by thiopurine methyltrans-


ferase (EC 2.1.1.67) (TPMT). The TPMT activity is controlled by a genetic polymorphism and the activity in RBC correlates with that in lymphoblasts, lymphocytes, platelets, liver, and kidney [4–7]. Population studies showed that the frequency distribution is trimodal with 88.6% of the subjects displaying high activity, 11.1% intermediate activity, and 1 out of 300 subjects having undetectable TPMT activity [8]. Thiopurine methylation requires AdoMet as methyl donor [9]. AdoMet is the universal methyl donor for many methyltransferase reactions of small molecules, DNA, RNA, proteins, and phospholipids, and plays an important role in the regulation of the action of these compounds [10].

Scheme 2 shows the transmethylation pathway with its principal metabolites, AdoMet, AdoHcy, homocysteine, and methionine. By donation of the methyl group, AdoMet is converted into AdoHcy, which is hydrolyzed into homocysteine and adenosine. Homocysteine can be degraded into cysteine in the transsulfuration pathway or remethylated into methionine. Two enzymes catalyze the remethylation of homocysteine. Betaine-homocysteine methyl-

‡ Corresponding author. Tel. 31-80-616933; FAX 31-80-616428.

§ Abbreviations: AdoHcy, S-adenosyl-L-homocysteine; AdoMet, S-adenosyl-L-methionine; ALL, acute lymphoblastic leukemia; 6MP, 6-mercaptopurine; MeMP(R), 6-methylmercaptopurine (riboside); MeM8OHP, 6-methylmercapto-8-hydroxypurine; MetIMP (MetIDP, MetITP), methylthioinosine mono- (di-, tri-) phosphate; MTX, methotrexate; RBC, red blood cells; tGMP (tGDP, tGTP), thioguaninosine mono- (di-, tri-) phosphate; tIMP, thioinosine monophosphate.

Received 8 September 1995; accepted 11 December 1995.



SCHEME 1. The metabolism of 6MP. 1, thiopurinemethyltransferase; 2, hypoxanthineguanine phosphoribosyltransferase (EC 2.4.2.8); M8OHP, 6-mercapto-8-hydroxypurine; PRPP, 5-phosphoribosyl-1-pyrophosphate.

transferase (EC 2.1.1.5) uses betaine as methyl donor and is active only in the liver [11]. 5-Methyltetrahydrofolate homocysteine methyltransferase (EC 2.1.1.13) is active in many, if not all, tissues and uses 5-methyltetrahydrofolate as methyl donor [11]. Next to its role in protein synthesis, the essential amino acid methionine can be activated as methyl donor by formation of AdoMet, using ATP as co-substrate [11].


Recently, we reported the effect of 6MP on the principal transmethylation metabolites *in vitro* [12]. Incubation of Molt-F4 human malignant ALL lymphoblasts with 6MP resulted in a decrease in AdoMet and the AdoMet/AdoHcy ratio, in an increase in AdoHcy and methionine in these cells, and a decreased release of homocysteine into the culture medium [12]. The decreased AdoMet/AdoHcy ratio could, theoretically, be caused by a depletion of the AdoMet pool due to its consumption for thiopurine methylation. However, similar effects on AdoMet, AdoHcy, methionine, and homocysteine were demonstrated after incubation of these cells with MeMPR, which already contains a methyl group. Thus, the effects of 6MP and MeMPR on these transmethylation metabolites were ascribed to the reduced conversion of methionine into AdoMet, due to ATP depletion produced by MetIMP [12]. More recently, we observed that incubation of Molt-F4 lymphoblasts with

6MP or MeMPR resulted in a decrease in the incorporation of [^{14}C] from [^{14}C]-methionine into total DNA [13], suggesting that thiopurines can influence DNA methylation *in vitro*.

It is well known that quantitative large amounts of 6MP are methylated *in vivo*. In RBC of ALL patients treated daily with oral 6MP ($75 \text{ mg} \cdot \text{m}^{-2}$), the median methylthioinosine nucleotide levels were $4.36 \text{ nmol}/8 \cdot 10^8 \text{ RBC}$ (range 0.25–22.5), compared to the much lower median thioguanine nucleotides levels of $335 \text{ pmol}/8 \cdot 10^8 \text{ RBC}$ (range 144–1263) [14]. Methylthioinosine nucleotide levels were even higher in RBC [15] and mononuclear cells [16], compared to those of thioguanine, when high doses of 6MP were administered intravenously. Influences of 6MP on the transmethylation metabolites *in vivo* have not been investigated up to now.

In the present study, we investigated influences of high-dose 6MP infusions on methylation capacity *in vivo*. In the consolidation treatment of the Dutch Childhood Leukemia Study Group (DCLSG-ALL-8 protocol) ALL patients are randomized for high-dose intravenous 6MP or low-dose oral 6MP. We investigated the oral 6MP group as the control group for the intravenous 6MP group, because both groups also received methotrexate (MTX) infusions. This inhibits dihydrofolate reductase (EC 1.5.1.3), causing a depletion of active tetrahydrofolate compounds (Scheme 2). Thus, it indirectly inhibits folate-dependent reactions, such as remethylation of homocysteine into methionine, purine *de novo* synthesis, and thymidylate synthesis [17].

The amounts of 6MP methylated *in vivo* were investigated by measurement of the methylated metabolites of 6MP in RBC, plasma, and urine. The influence of the infusions on the transmethylation metabolites was investigated by measurement of methionine and homocysteine in plasma and AdoMet, AdoHcy, and purine nucleotides intracellularly. Lymphoblasts were not available for investi-



SCHEME 2. The transmethylation pathway. 1, thiopurine-methyltransferase and other AdoMet-dependent methyltransferases; 2, dihydrofolate reductase; 3, 5-methyltetrahydrofolate homocysteine methyltransferase; DHF/THF, di/tetra hydrofolate.

gation, because the patients were in complete remission. We used RBC, because TPMT activity in RBC correlates with that in lymphoblasts and other tissues [4–7]. RBC can synthesize 5-phosphoribosyl-1-pyrophosphate [18], an essential cofactor for the conversion of 6MP into tIMP, but do not manifest an active purine *de novo* synthesis, as ALL lymphoblasts do [19].

METHODS

Ten children with ALL were treated in our center according to the DCLSG-ALL-8 protocol with a consolidation therapy of high-dose MTX ($5 \text{ g} \cdot \text{m}^{-2}$ in 24 hr, 4 courses in 8 weeks). Leucovorin rescue (Scheme 2) was started at 36 hr after the MTX infusion was begun and continued every 6 hr until MTX plasma levels were less than $0.25 \text{ } \mu\text{M}$. Five of the 10 patients were randomized for oral 6MP ($25 \text{ mg} \cdot \text{m}^{-2}$ daily for 8 weeks, starting 7 days before the first MTX course) and the other 5 received 6MP intravenously ($1300 \text{ mg} \cdot \text{m}^{-2}$ in 24 hr, from 24 until 48 hr after MTX infusion, 4 courses in 8 weeks). Patient or parental approval was obtained according to the ethical guidelines of our hospital.

Blood was sampled during the 4 courses of all patients in the oral and intravenous group, before and 24, 28, 48, 52 and 72 hr after the MTX infusion was begun. Plasma and RBC were isolated as described [20]. RBC transfusions, an essential part of the supportive treatment during the intensive consolidation treatment, were given between the courses, but never during a course. Dithiothreitol was added to plasma, RBC, and urine to prevent oxidation of the thiol groups [20]. Urine was collected during the 24 hr of the 6MP infusion as well as during the next 24 hr, either as a pooled 24-hr sample or as fractionated samples of approximately 6 hr. In children with nappies, we collected one urine sample at the end of the infusion. The methylated metabolites of 6MP and the purine nucleotides were extracted and measured with HPLC using ultraviolet absorbance. Detection limits for the methylated metabolites in plasma were 20–50 nM and for MetIMP 11 pmol per 100 μL injection [20]. A previously indeterminate metabolite of 6MP [20] was identified as MeM8OHP. It was measured as the other methylthiopurine metabolites and eluted at 30 min [20]. Total homocysteine was measured with HPLC after reduction with sodium borohydride and derivatization with monobromobimane [21]. Methionine was measured as described [12]. AdoMet and AdoHcy were extracted from 200 μL RBC ($2\text{--}3 \cdot 10^{12}$ RBC/L 0.9% (w/v) saline with 0.1% (w/v) dithiothreitol) and 200 μL water with 40 μL 55% trichloroacetic acid and kept on ice for 10 min. After centrifugation, 300 μL of the supernatants were washed 3 times with 2 volumes of peroxide-free diethylether to remove the trichloroacetic acid. The samples were flushed with nitrogen to a final volume of 150 μL . AdoMet and AdoHcy were measured with HPLC [12] at 248, 254, and 260 nm.

RESULTS

Methylated Metabolites of 6MP in Plasma, RBC, and Urine

Figure 1 shows the mean levels of the methylated metabolites of 6MP in plasma of the intravenous 6MP group. Steady state levels of 6MP and MeMP were 11.6 (sem 1.6) and 0.6 (sem 0.1) μM , respectively. MeM8OHP reached levels of 2.6 (sem 0.5) μM during the 6MP infusion. Upon its termination, MeMP and MeM8OHP were rapidly cleared from plasma. MeM8PR increased slowly during the 6MP infusion and reached levels of 0.3 (sem 0.05) μM 24 hr after its termination. Methylthioxanthine and methylthiouric acid were not detectable in plasma of these patients.

Figure 2 shows the levels of MetIMP, MetIDP, and MetITP in RBC of patients in the intravenous 6MP group. These levels increased during and after the infusion. At 72 hr, the mean levels of MetIMP were 3.1 (sem 0.6), of MetIDP 0.8 (sem 0.3), and of MetITP 1.4 (sem 0.4) nmol/ 10^8 RBC. At the start of the next course, the mean




FIG. 1. Methylated metabolites of 6MP in plasma of the intravenous 6MP group. Patients were treated with an MTX infusion from 0–24 hr and a 6MP infusion from 24–48 hr. The means of all courses and all patients are indicated by the markers, the error bars indicate the SEM.




FIG. 2. Methylated metabolites of 6MP in RBC of the intravenous 6MP group. Patients were treated with an MTX infusion from 0–24 hr and a 6MP infusion from 24–48 hr. The means of all courses and all patients are indicated by the markers, the error bars indicate the SEM.

MetIMP levels were decreased to less than one tenth of the level at 72 hr of the previous course, whereas those of MetIDP were one half and of MetITP one third. Four children each received one RBC transfusion between the courses. After this, the methylthioinosine nucleotide levels at the start of the next course were in the same range or higher, compared to those of the previous course. Interindividual variation coefficients of 6MP and the methylated metabolites in plasma and RBC were between 30 and 50%.

In urine 6MP, thioxanthine, and thiouric acid were the main metabolites. MeMP, MeM8OHP, methylthioxanthine, and methylthiouric acid were not detectable in urine. MeMPR accounted for less than 2% of all excreted metabolites of 6MP in urine during the 6MP infusion.

Urine of the oral group was not collected. In plasma and RBC samples of the oral 6MP group at 0, 24, 28, 48, 52, and 72 hr, none of the metabolites of 6MP was detectable. Oral 6MP ($25 \text{ mg} \cdot \text{m}^{-2}$) was given at 7 a.m., whereas blood was sampled at 1 or 5 p.m..

Purine Nucleotides in RBC

Adenine and guanine nucleotide levels in RBC of the oral and intravenous 6MP group were in the normal range [22] and remained constant during the MTX and 6MP infusions of all courses. ATP levels were 13.1 (sem 0.9) $\text{nmol}/10^8$ RBC.

AdoMet and AdoHcy in RBC

AdoMet levels were analyzed in both groups, but were not detectable in any of the samples. The detection limit of AdoMet in RBC is $20 \text{ pmol}/10^8$ RBC. AdoHcy levels remained constant in both groups. Mean AdoHcy levels were 10.8 (sem 1.3) $\text{pmol}/10^8$ RBC in the intravenous and 9.1 (sem 1.0) $\text{pmol}/10^8$ RBC in the oral group.

Methionine and Homocysteine in Plasma (Fig. 3)

In both groups, homocysteine levels increased by 130–250% upon administration of MTX and returned to initial values after the start of leucovorin administration. Until 48 hr, there were no significant differences in homocysteine levels between the groups but, at 52 and 72 hr, they were significantly lower in the intravenous group (*t*-test, two-tailed, $P = 0.03$ and 0.002 , respectively, *df* 34, all courses). Methionine levels decreased by 35–50% from 0 to 24 hr during all courses in the oral group and during the third and fourth course in the intravenous group. This decrease in methionine was not present during the first or second course in the intravenous group. After termination of the MTX infusion, methionine levels immediately returned to initial levels in the oral group. In the intravenous group, methionine levels began to increase 4 hr after termination of the 6MP infusion and reached levels 137% above the initial levels at 72 hr. At 48 and 52 hr, methionine levels were significantly higher in the oral group (*t*-test, two-tailed, $P = 0.05$ and 0.05 , respectively, *df* 33, all courses). At 0, 24, 28, and 72 hr, there were no significant differences. Methionine in unwashed RBC of 10 random samples of the oral and intravenous 6MP group was in the range of 60 – $200 \text{ pmol}/10^8$ RBC.

DISCUSSION

The importance of a balanced transmethylation pathway and its role in carcinogenesis and malignancy has been stressed by several studies and reviewed by Laird and Jaenisch [23]. The methylation pattern of DNA of human malignant cells is often characterized by widespread hypomethylation, regional hypermethylation, and elevated expression levels of DNA methyltransferase activity. In animals, the administration of AdoMet was able to prevent or even reverse the development of tumors, whereas methyl-deficient diets were able to induce tumors, which is consistent with the widespread hypomethylation in tumor DNA [23]. Recently, it was shown that DNA methyltransferase




FIG. 3. Homocysteine (triangles) and methionine (circles) in plasma of the oral (solid lines) and intravenous (dotted lines) 6MP group. Patients in both groups were treated with a MTX infusion from 0–24 hr. Patients in the oral group received 6MP daily p.o., whereas patients in the intravenous 6MP group received 6MP as an infusion from 24–48 hr. The means of all courses and all patients are indicated by the markers, the error bars indicate the SEM.

activity contributes substantially to the development of intestinal adenomas [24]. However, it remains unclear whether or not changes in the methylation status (i.e. methionine metabolites, DNA methyltransferase activity, or DNA methylation) play a causal role in carcinogenesis or are a property of the malignant cell. Even without this knowledge, the methylation status might be a target for chemotherapeutic agents. In line with this view, we recently demonstrated that incubation of Molt F4 lymphoblasts with 6MP resulted in changes in the concentrations of transmethylation metabolites [12] and in DNA methylation [13].

The present study is the first to investigate the influence of high-dose 6MP on transmethylation metabolites *in vivo*. Large amounts of methylated thiopurines were detectable in plasma and RBC after high-dose intravenous 6MP, with interpatient variabilities of 30–50% (Fig. 1, 2). TPMT activities in peripheral mononuclear cells ranged from 4.6–16.1 IU/ 10^9 cells in the present group, demonstrating in-

termediate and high activity [25]. The genetic polymorphism of TPMT may be partially responsible for the interpatient variability. We could not demonstrate a correlation between TPMT activity and (methyl)thiopurines, because a high percentage of TPMT assays in mononuclear cells fail due to the lack of cells in leukopenic patients as well as other enzymes involved in thiopurine metabolism (Scheme 1) [25]. Measurement of TPMT in RBC would not be informative because RBC are transfused during the induction and consolidation treatment. The presence of methylated metabolites of 6MP in urine was less pronounced, compared to that in plasma and RBC. The absence of MeMP and MeM8OHP in urine might be the result of oxidation [26] or glucuronidation [27] of these compounds or of desulfuration of the drug [27]. Methylthioxanthine and methylthiouric acid were not detectable in plasma or urine, which is in concordance with the results obtained from patients treated with 6MP and MeMP [28] and with *in vitro* data demonstrating that thioxanthine and thiouric acid are inhibitors of TPMT [29].

In the oral group, 6MP and its metabolites were not detectable in plasma nor RBC. Blood sampling was timed after the start of MTX, as in the intravenous group, and not after 6MP intake. Detection of mono-, di- and triphosphate nucleotides in RBC requires higher intracellular concentrations of methylthioinosine nucleotides compared to measurement of MeMP after hydrolysis of the nucleotides. The administered dose ($25 \text{ mg} \cdot \text{m}^{-2}$ daily for 8 weeks) was one third of the dose administered daily during 1.5–2-year maintenance therapy of ALL [14], too low for detection of methylthioinosine nucleotides in the oral group.

The high levels of methylthioinosine nucleotides in RBC in the intravenous group indicate that the transmethylation rate and, thus, the rate of AdoMet synthesis must have been high in RBC. AdoMet levels were below the detection limit in all RBC samples, but the increasing levels of methylthioinosine nucleotides in RBC after termination of the infusion indicate that sufficient AdoMet was available for this methylation reaction. In RBC of healthy controls, mean AdoMet levels were $3.5\text{--}5.2 \mu\text{mol/L}$ packed fresh RBC (30–32) ($\pm 10 \cdot 10^{12}$ RBC/1 packed cells). Roughly, these levels are just above our detection limit ($20 \text{ pmol}/10^8$ RBC). AdoHcy levels were approximately $10 \text{ pmol}/10^8$ RBC and remained constant during the MTX and 6MP infusions. In one study, mean AdoHcy levels were one third of those of AdoMet in fresh RBC of healthy subjects [31] whereas, in our study, AdoMet levels were lower than AdoHcy levels. We used stored RBC from patients treated for leukemia, which may have influenced the difference. We are not aware of a study having been conducted on AdoMet and AdoHcy levels in RBC under similar conditions.

Changes in homocysteine and methionine levels in plasma were observed in both groups. The increase in homocysteine and the decrease in methionine in plasma after the start of MTX administration could be ascribed to the decreased remethylation of homocysteine, itself the result

of the decreased availability of tetrahydrofolate derivatives due to inhibition of dihydrofolate reductase by MTX (Scheme 2). These changes have also been demonstrated by other [33–35]. A decrease in methionine levels was not detectable during the first two courses in the intravenous group, probably because we did not measure between 0 and 24 hr when the nadir was reached [35].

After termination of the MTX infusion, methionine and homocysteine levels were different for the two groups. Upon leucovorin administration, homocysteine levels decreased in both groups, but decreased to significantly lower levels at 52 and 72 hr in the intravenous 6MP group. Methionine levels increased immediately to initial levels after termination of the MTX infusion in the oral group, but remained low in the intravenous group during the 6MP infusion, after which they rebounded above initial levels. Because leucovorin, which increases methylation of homocysteine into methionine, was administered 12 hr after the start of the 6MP infusion, the pure effect of high-dose 6MP on the transmethylation metabolites may be masked. The delay in the recovery of methionine after termination of the MTX infusion in the intravenous group may be the result of the high consumption of methionine for methylation of thiopurines.

Thus, our study in children with ALL in remission shows an effect of high-dose 6MP in plasma (i.e. a delay in the recovery of the decrease in methionine due to MTX). This study does not show evidence for an effect of high-dose 6MP in RBC. This does not exclude the possibility that high-dose 6MP influences the transmethylation metabolites in the lymphoblasts. However, as all patients were in complete remission during the consolidation treatment, lymphoblasts are not available. It would be worthwhile to investigate the effects of high-dose 6MP alone on the transmethylation pathway in the lymphoblasts immediately after diagnosis, which will probably be done in a window phase of the next DCLSG study (ALL-9).

The authors acknowledge the technical assistance of A. C. de Graaf-Hess, B. van Raay-Selten, J. M. van Baal, J. J. Keizer-Garritsen and M. A. H. Lambooy. 6-Methylmercapto-8-hydroxypurine was provided by Dr. G. B. Elion, Wellcome Research Laboratories, Research Triangle Park, NC 27709, U.S.A. This study was supported by a grant from the Dutch Cancer Society (NUKC-92-79).

References

- Tidd DM and Paterson AR, A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. *Cancer Res* 34: 738–746, 1974.
- Bökkerink JPM, Stet EH, De Abreu RA, Damen FJ, Hulscher TW, Bakker MA and van Baal JM, 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. *Biochem Pharmacol* 45: 1455–1463, 1993.
- Stet EH, De Abreu RA, Janssen YP, Bökkerink JPM and Trijbels JMF, A biochemical basis for synergism of 6-mercaptopurine and mycophenolic acid in Molt F4, a human malignant T-lymphoblastic cell line. *Biochim Biophys Acta* 1180: 277–282, 1993.
- McLeod HL, Relling MV, Liu Q, Pui CH and Evans WE, Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. *Blood* 85: 1897–1902, 1995.
- Van Loon JA and Weinshilboum RM, Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. *Biochem Genet* 20: 637–658, 1982.
- Woodson LC, Dunnette JH and Weinshilboum RM, Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. *J Pharmacol Exp Ther* 222: 174–181, 1982.
- Szumanski CL, Honchel R, Scott MC and Weinshilboum RM, Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. *Pharmacogenetics* 2: 148–159, 1992.
- Weinshilboum RM and Sladek SL, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *Am J Hum Genet* 32: 651–662, 1980.
- Remy CN, Metabolism of thiopyrimidines and thiopurines. S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. *J Biol Chem* 238: 1078–1084, 1963.
- Borchardt RT, S-Adenosyl-L-methionine-dependent macromolecule methyltransferases: potential targets for the design of chemotherapeutic agents. *J Med Chem* 23: 347–357, 1980.
- Finkelstein JD, Methionine metabolism in mammals. *J Nutr Biochem* 1: 228–236, 1990.
- Stet EH, De Abreu RA, Bökkerink JPM, Blom HJ, Lambooy LHJ, Vogels-Mentink TM, Graaf-Hess AC de, Raay-Selten Bvan and Trijbels JMF, Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts. *Biochem J* 304: 163–168, 1994.
- De Abreu RA, Lambooy LHJ, Stet EH, Vogels-Mentink TM and Heuvel Lvd, Thiopurine induced disturbance of DNA methylation in human malignant cells. *Adv Enz Regul* 35: 251–263, 1995.
- Lennard L, Gibson BE, Nicole T and Lilleyman JS, Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. *Arch Dis Child* 69: 577–579, 1993.
- Duchesne K, Latour S, Leclerc JM, Sallan SE and Theoret Y, Pharmacokinetics of oral and intravenous 6-mercaptopurine in childhood acute lymphoblastic leukemia. *Proc Am Soc Clin Oncol* 13:(Abs) 137, 1995.
- Keuzenkamp-Jansen CW, Bökkerink JPM, Trijbels JMF, Heijden MAH and De Abreu RA, Intracellular pharmacology and biochemistry of methotrexate and 6-mercaptopurine in childhood acute lymphoblastic leukemia. In: *Purine and Pyrimidine Metabolism in Man VIII*, (Eds. Sahota A and Taylor MW) pp. 115–118. New York: Plenum Publishing, 1995.
- Bertino JR, Karnofsky memorial lecture. Ode to methotrexate. *J Clin Oncol* 11: 5–14, 1993.
- Hershko A, Razin A and Mager J, Regulation of the synthesis of 5-phosphoribosyl-I-pyrophosphate in intact red blood cells and in cell-free preparations. *Biochim Biophys Acta* 184: 64–76, 1969.
- Scholar EM and Calabresi P, Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells. *Cancer Res* 33: 94–103, 1973.
- Keuzenkamp-Jansen CW, De Abreu RA, Bökkerink JPM and Trijbels JMF, Determination of extracellular and intracellular thiopurines and methylthiopurines with HPLC. *J Chromatogr B* 672: 53–61, 1995.
- TePoele-Pothof MWTB, Berg Mvd, Franken DG, Boers GHJ, Jakobs C, Kroon IFI de, Eskes TKAB, Trijbels JMF and Blom

- HJ, Three different methods for the determination of total homocysteine in plasma. *Ann Clin Biochem* 32: 218–220, 1995.
22. Korte Dde, Haverkort WA, van Gennip AH and Roos D, Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography. *Anal Biochem* 147: 197–209, 1985.
 23. Laird PW and Jaenisch R, DNA methylation and cancer. *Hum Mol Gen* 3: 1487–1495, 1994.
 24. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA and Jaenisch R, Suppression of intestinal neoplasia by DNA hypomethylation. *Cell* 81: 197–205, 1995.
 25. Keuzenkamp-Jansen CW, Leegwater PAJ, De Abreu RA, Lambooy MAH, Bökkerink JPM and Trijbels JMF, Thiopurine methyltransferase activity: a review and clinical pilot study. *J Chromatogr B*, in press.
 26. Krenitsky TA, Neil SM, Elion GB and Hitchings GH, A comparison of the specificities of xanthine oxidase and aldehyde oxidase. *Arch Biochem Biophys* 150: 585–599, 1972.
 27. Elion GB, Biochemistry and pharmacology of purine analogs. *Fed Proc* 26: 898–904, 1967.
 28. Elion GB, Callahan S, Rundles RW and Hitchings GH, Relationship between metabolic fates and antitumor activities of thiopurines. *Cancer Res* 23: 1207–1217, 1963.
 29. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W and Weinshilboum RM, Purine substrates for human thiopurine methyltransferase. *Biochem Pharmacol* 48: 2135–2138, 1994.
 30. Legendijk J, Ubbink JB and Vermaak WJ, Quantification of erythrocyte S-adenosyl-L-methionine levels and its application in enzyme studies. *J Chromatogr* 576: 95–101, 1992.
 31. Barber JR, Morimoto BH, Brunauer LS and Clarke S, Metabolism of S-adenosyl-L-methionine in intact human erythrocytes. *Biochim Biophys Acta* 886: 361–372, 1986.
 32. Oden KL and Clarke S, S-adenosyl-L-methionine synthetase from human erythrocytes: role in the regulation of cellular S-adenosylmethionine levels. *Biochemistry* 22: 2978–2986, 1983.
 33. Refsum H, Ueland PM and Kvinnsland S, Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. *Cancer Res* 46: 5385–5391, 1986.
 34. Refsum H, Wesenberg F and Ueland PM, Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. *Cancer Res* 51: 828–835, 1991.
 35. Broxson EHJ, Stork LC, Allen RH, Stabler SP and Kolhouse JF, Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. *Cancer Res* 49: 5879–5883, 1989.